On October 21, 2021 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligand’s BEPro technology (Press release, Ligand, OCT 21, 2021, View Source [SID1234591822]). Ligand will receive an upfront payment in respect of the collaboration, and if the program advances, clinical and regulatory milestone payments, and tiered royalties on net sales. CRDC will be responsible for all costs related to the program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles. Ligand has generated preclinical pharmacokinetics data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous comparators. Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds.
"This transaction with CRDC is another deal in a long history of success converting our inventions, data and intellectual property into licenses to advance important medicines and deliver value to our shareholders," said John Higgins, CEO of Ligand Pharmaceuticals. "We are proud of the important work our team has contributed toward addressing the pandemic and are pleased with this new collaboration. China Resources Group is one of the largest Chinese pharmaceutical companies and is looking forward to robust development of this program through their subsidiary CRDC."